Abstract
Sesuvium sesuvioides was used to treat inflammation, arthritis, gout, and thyroid dysfunction. The current study evaluated the antihyperthyroidism effect of S. sesuvioides to consolidate its traditional use. High-performance liquid chromatography (HPLC) analysis of S. sesuvioides methanol extract revealed the presence of phenolics such as gallic acid (0.73 ppm/mg), benzoic acid (11.22 ppm/mg), p-coumaric acid (3.12 ppm/mg), ferulic acid (5.47 ppm/mg), cinnamic acid (3.54 ppm/mg), and sinapic acid (3.17 ppm/mg). In vivo hyperthyroidism was induced using thyroxine in vivo, which increased T(3) (triiodothyronine), T(4) (tetraiodothyronine), malondialdehyde (MDA), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) levels. However, it reduced thyroid stimulating hormone (TSH), superoxide dismutase (SOD), and reduced glutathione (GSH). S. sesuvioides methanol extract alleviated thyroxine-induced intoxication in a dose-dependent manner. At a 750 mg/kg (SsCr(3)) dose, it reduced T(3), T(4), MDA, IL-6, and TNF-α by 61.23, 41.29, 45.17, 44.66, and 62.03%, respectively, and elevated TSH, SOD, and GSH by 365.52, 94.45, and 95.12%, respectively, relative to the diseased group. Further confirmation was done by histopathological examination, which showed normal thyroid histology where follicles were filled with colloids with more cytoplasmic concentrations. This activity is undoubtedly correlated to the richness of the extract by phenolic acids, as revealed by HPLC. In silico ADME/TOPKAT prediction performed on the secondary metabolites identified in S. sesuvioides methanol extract revealed acceptable pharmacodynamic, pharmacokinetic, and toxicity potential. Thus, S. sesuvioides could serve as a promising source for alleviating hyperthyroidism, which could be further incorporated into pharmaceutical preparations.